Your browser doesn't support javascript.
Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis.
Daniels, Vincent; Saxena, Kunal; Roberts, Craig; Kothari, Smita; Corman, Shelby; Yao, Lixia; Niccolai, Linda.
  • Daniels V; Center for Observational and Real-World Evidence, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. Electronic address: Vincent_daniels@merck.com.
  • Saxena K; Center for Observational and Real-World Evidence, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. Electronic address: kunal.saxena@merck.com.
  • Roberts C; Center for Observational and Real-World Evidence, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. Electronic address: craig.roberts@merck.com.
  • Kothari S; Center for Observational and Real-World Evidence, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. Electronic address: smita.kothari@merck.com.
  • Corman S; OPEN Health, 4350 East-West Highway Suite 1100, Bethesda, MD 20814, USA. Electronic address: shelbycorman@openhealthgroup.com.
  • Yao L; Center for Observational and Real-World Evidence, Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. Electronic address: lixia.yao@merck.com.
  • Niccolai L; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, PO Box 208034, 60 College Street, New Haven, CT 06520-8034, USA. Electronic address: linda.niccolai@yale.edu.
Vaccine ; 39(20): 2731-2735, 2021 05 12.
Article in English | MEDLINE | ID: covidwho-1193499
Semantic information from SemMedBD (by NLM)
1. IMPACT gene INHIBITS Human Papilloma Virus Vaccine
Subject
IMPACT gene
Predicate
INHIBITS
Object
Human Papilloma Virus Vaccine
2. IMPACT gene INHIBITS Human Papilloma Virus Vaccine
Subject
IMPACT gene
Predicate
INHIBITS
Object
Human Papilloma Virus Vaccine
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has significantly affected utilization of preventative health care, including vaccines. We aimed to assess HPV vaccination rates during the pandemic, and conduct a simulation model-based analysis to estimate the impact of current coverage and future pandemic recovery scenarios on disease outcomes. The model population included females and males of all ages in the US. The model compares pre-COVID vaccine uptake to 3 reduced coverage scenarios with varying recovery speed. Vaccine coverage was obtained from Truven Marketscan™. Substantially reduced coverage between March-August 2020 was observed compared to 2018-2019. The model predicted that 130,853 to 213,926 additional cases of genital warts; 22,503 to 48,157 cases of CIN1; 48,682 to 110,192 cases of CIN2/3; and 2,882 to 6,487 cases of cervical cancer will occur over the next 100 years, compared to status quo. Providers should plan efforts to recover HPV vaccination and minimize potential long-term consequences.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Alphapapillomavirus / Papillomavirus Vaccines / COVID-19 Type of study: Prognostic study Limits: Female / Humans / Male Country/Region as subject: North America Language: English Journal: Vaccine Year: 2021 Document Type: Article

Full text: Available Collection: International databases Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Alphapapillomavirus / Papillomavirus Vaccines / COVID-19 Type of study: Prognostic study Limits: Female / Humans / Male Country/Region as subject: North America Language: English Journal: Vaccine Year: 2021 Document Type: Article